CARM: Carisma Tx Analyst Consensus Forecast
Carisma Therapeutics (CARM) maintains laboratories for creating oncology-profile macrophages in Pennsylvania, while drug production is outsourced to external US CDMO facilities; this daily price chart for CARM reflects asset dynamics where the indicator equals 1.00. The business relies on a scientific foundation and partnerships to develop anti-tumor therapies. In the race for leadership in cell therapy, Carisma Therapeutics (CARM) depends on patent protection, focusing on the safety of its methods.
Analytical breakdowns for Carisma Therapeutics (CARM)
- market price and analyst price targets:
- market capitalization information:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Carisma Therapeutics|CARM - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital carismatx.com|CARM - Company Aggregate Debts|Debts to Book Capitalization Carisma Tx|CARM - Company Long-Term Debt|Company Short-Term Loans and Borrowings Carisma Therapeutics|Quick Liquidity Indicator carismatx.com
- earnings and valuation multiples information:
CARM - Net Profit|Projected Future Earnings Carisma Therapeutics|CARM - Price to Earnings Ratio|Future Price to Earnings Multiple carismatx.com|CARM - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Carisma Tx|CARM - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Carisma Therapeutics|CARM - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months carismatx.com|CARM - Net earnings per share growth this year|Earnings growth forecast for next year Carisma Therapeutics
General company analysis:CARM Carisma Therapeutics Inc
This indicator represents the arithmetic mean of leading experts' expectations regarding the asset's fair value, allowing market noise to be filtered out from the fundamental valuation. By analyzing the consensus target price forecast at 1.00, an investor gains a comprehensive assessment of the potential for Carisma Therapeutics (CARM), which directly depends on the efficiency of cell product development outsourcing and successes in the field of immunotherapy.
Competitors of Carisma Therapeutics
Consensus Target argenx.com ARGX|Analyst Consensus Forecast BNTX (BioNTech)|Analyst Consensus Forecast Abivax SA ABVX|ADMA - Price Target Chart|Fair Value Consensus PTGX (Protagonist Corp)|Immunovant, Inc. (IMVT) - Price Target Chart|Consensus Target kiniksa.com|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|Aclaris Therapeutics, Inc (ACRS) - Consensus Target|KYTX: Analyst Consensus Forecast|tizianalifesciences.com (TLSA) - Analyst Consensus Forecast|Price Target Chart Cabaletta Bio|VTYX: Fair Value Consensus|Analyst Consensus Forecast THTX|Analyst Median Target Avalo Therapeutics Inc|Price Target Chart Eledon Pharmaceuticals ELDN|Analyst Median Target agenusbio.com (AGEN)|CLYM - Price Target Chart|zurabio.com (ZURA) - Consensus Target|ATYR: Analyst Consensus Forecast|Adagene Inc. (ADAG) - Analyst Consensus Forecast|Consensus Target IMA|STTK: Fair Value Consensus|Consensus Target EQ (Equillium, Inc.)|Analyst Forecast Prices CNTB|Analyst Consensus Forecast IMUX (Immunic)|Fair Value Consensus ATRA|InflaRx GmbH - Analyst Consensus Forecast|Average Forecast Price x4pharma.com|adicetbio.com (ACET) - Price Target Chart|Celularity - Fair Value Consensus|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Analyst Consensus Forecast Barinthus Biotherapeutics Corp|Price Target Chart Kezar Life Sciences (KZR)|SABS: Forecast Levels Chart|Analyst Consensus Forecast AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Average Forecast Price|QTTB: Consensus Target|GOVX - Analyst Consensus Forecast|EDSA (Edesa Biotech, Inc.) - Consensus Target|IBIO: Analyst Forecast Prices|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Bolt Bio (BOLT) - Analyst Median Target|Analyst Consensus Forecast HCWB|Consensus Target aptevotherapeutics.com APVO|Price Target Chart AIM ImmunoTech AIM|Analyst Median Target Aditxt Inc. (ADTX)|GRI Bio - Analyst Consensus Forecast|XORTX Therapeutics Inc (XRTX) - Consensus Target|HIND: Analyst Consensus Forecast|Revelation Biosciences Corp (REVB) - Analyst Consensus Forecast|Price Target Chart Indaptus Therapeutics|SCNI: Fair Value Consensus|Price Target Chart CalciMedica, Inc. (CALI)|Consensus Target affimed.com AFMD|Price Target Chart Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Forecast Levels Chart|IGM Bio - Analyst Consensus Forecast|Fair Value Consensus ITOS (iteostherapeutics.com)|OCEA: Analyst Consensus Forecast|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|Price Target Chart Third Harmonic Bio, Inc
